Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Free Cash Flow (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Free Cash Flow data on record, last reported at -$22.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 11.2% year-over-year to -$22.3 million; the TTM value through Dec 2025 reached -$86.1 million, up 14.97%, while the annual FY2025 figure was -$86.1 million, 14.97% up from the prior year.
  • Free Cash Flow reached -$22.3 million in Q4 2025 per FHTX's latest filing, down from -$18.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $271.3 million in Q1 2022 and bottomed at -$32.0 million in Q2 2023.
  • Average Free Cash Flow over 5 years is -$8.3 million, with a median of -$24.1 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 668.14% in 2021, then surged 1225.43% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $11.8 million in 2021, then crashed by 347.36% to -$29.2 million in 2022, then rose by 9.61% to -$26.4 million in 2023, then rose by 4.75% to -$25.1 million in 2024, then increased by 11.2% to -$22.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$22.3 million in Q4 2025, -$18.9 million in Q3 2025, and -$21.0 million in Q2 2025.